Merck Gains Rights to KalVista’s Ocular Therapy

12.10.2017 - US drugmaker Merck has agreed to pay KalVista Pharmaceuticals more than $750 million to gain the rights to KVD001, an investigational treatment for diabetic macular edema (DME), as...